FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Attar Eyal C.						2. Issuer Name and Ticker or Trading Symbol Vor Biopharma Inc. [VOR]									ck all app Direc Office	tor er (give title	ng Pers	10% O	wner
(Last) (First) (Middle) C/O VOR BIOPHARMA INC. 100 CAMBRIDGEPARK DRIVE, SUITE 101						3. Date of Earliest Transaction (Month/Day/Year) 12/27/2024									below	n EF MEDI	CAL	below) OFFICE	R
(Street) CAMBRIDGE MA 02140 (City) (State) (Zip)				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable ine) Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					tion	Execution Date,						es Acquired (A) Of (D) (Instr. 3,		A) or	5. Amo Securit Benefic	unt of ies cially Following	Form:	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) (D)	or F	rice	Transa	ction(s) 3 and 4)			(mou. 4)	
Common Stock 12/27/2					.024						10,334	Ι) :	\$1.25	81,439			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Executi if any	xecution Date, any		4. Transaction Code (Instr. 8)		of		Exerci on Da Day/Y		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Ser.	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y [0	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code V		(A)	(D)	Date Exercis	able	Expiration Date	Title Share							

Explanation of Responses:

1. The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024.

/s/ Katie Kazem, Attorney-in-

Fact

12/31/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.